comprehensive -WSS

comprehensive

author：leisure time 2025-10-02 19:15:56 - browse：93181

Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups.

The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.

First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. Around $25.6 billion had been raised by 556 first-time funds in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Chemotherapy shortages won’t get better under Biden’s latest plan

focus

hotspot

WSS

Radiology is caught between AI's potential and concern for patients

Listen: Biogen's messy board & Laronde's data problem

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

Russia says it foiled Ukrainian drone attack on Moscow as Kyiv's counteroffensive grinds on

Supreme Court wrestles with OxyContin maker's bankruptcy deal

7 people shot in DC, police say

hotspot

comprehensive

hotspot

Medicare proposal to cover medical devices draws a mixed reaction

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

State Dept. review finds Biden bears some blame for Afghanistan failures

Can food be medicine? And other questions about a new push

Sports medicine is finally prioritizing gender equality

FDA approves world's first CRISPR

Walensky prepares to leave CDC — and Congress — behind

Chemotherapy shortages won’t get better under Biden’s latest plan

As demand for Covid shots wanes, Moderna seeks its next success

Option Care buys Amedisys in $3.6 billion home care deal

hotspot

Van's Gluten Free Original Waffles recalled for possible wheat allergen

AI models in health care face new federal disclosure requirements

Meta looks to target Twitter with a rival app called Threads

Community addresses injustice for Long Island mothers

Why is France rioting? What to know about the fatal police shooting of Nahel M

PhRMA sues HHS over Medicare drug price negotiation

entertainment

focus

hotspot

hotspot